Anti Inflammatory Drug May Prevent Type 2 Diabetes
Monday, November 30th, 2009Researchers at the Joslin Diabetes Center are reporting that an budget-priced anti-inflammatory drug equivalent to aspirin, salsalate, may prevent strain 2 diabetes by lowering blood glucose and reducing inflammation.
The study, which appears in the February to be decided disagree of Diabetes Vigilance, is a small, proof-of-principal clinical trial, but is promising plenty to spur three more trials to see if the drug, salsalate, can also treat diabetes by lowering blood glucose, slow the progression of coronary artery affliction in those with metabolic syndrome, and perhaps anticipate diabetes in those at high risk.
“This is far-out because salsalate has a allowable safety promote after myriad years of end, is inexpensive to make and appears to prepare the potential to diminish blood glucose,” said Allison B. Goldfine, M.D., dispose researcher on the boning up, Manage of Clinical Research at Joslin and Assistant Professor at Harvard Medical School. “It may be functional in preventing diabetes.”
While it has long been known that high doses of aspirin could break blood glucose levels, the risk of tolerate bleeding is too pongy chief to grant for this treatment to be used, she said. It has also been known for specific years that inflammatory markers and proteins are elevated in people with diabetes and that aspirin can reduce redness, she noted.
Animal studies had shown aspirin could be effective, but since it could not safely be Euphemistic pre-owned in humans at steep doses, the researchers concern about deceitful a trendy drug. Goldfine suggested trying salsalate, a non-steroidal, anti-inflammatory medication that is similar to aspirin but does not cause bleeding in patients at risk for diabetes. The cheap drug has been used as regards decades to play host to arthritis.
The treacherous-masked, placebo-controlled study of 20 obese young adults found that salsalate substantially reduced blood glucose levels as spout as inflammation, and, as a result, may grieve their chance of developing type 2 diabetes.
“Our study was the first to look at the metabolic changes that be brought to someone’s attention when you send salsalate to obese people who have not yet developed diabetes and we’re exceedingly encouraged by what we found,” she said.
The review ground that those who took 4 grams of salsalate per day in favour of identical month reduced fasting glucose levels by 13 percent and levels of C-reactive protein, a marker in support of redness, by 34 percent. Earlier studies have implicated inflammation in the advance of fount 2 diabetes and heart disease.
The proof-of-assets survey concludes that salsalate reduces glycemia and may improve inflammatory cardiovascular risk indexes in the stout. The findings be supportive of the proposition that long-lasting inflammation contributes to rotundity-akin abnormal blood glucose and suggests that targeting inflammation may provide a group therapy for the duration of diabetes avoidance.
This study was funded by grants from the National Institutes of Constitution; the Joslin Diabetes and Endocrinology Research Center; a Joslin Eli Lilly Fellowship Allowance; and the Clinical Investigator Training Program of Harvard-MIT Health Sciences and Technology-Beth Israel Deaconess Medical Center, in collaboration with Pfizer Inc., and Merck & Company, Inc.
Other researchers participating in the go into were Amy Fleischman, M.D., MMSc; Steven E. Shoelson, M.D., Ph.D.; and Raquel Bernier, B.S.
Additional Salsalate Trials
The encouraging results from this proof-of-principal study have prompted very many related studies.
Dr. Goldfine is the pre-eminent investigator in one workroom that targets inflammation using salsalate in patients with metabolic syndrome, assessing effects of coronary artery plaque size. This project is funded by the National Heart, Lung and Blood Institute and hand down begin enrollment in winter 2008. There is a lifestyle intervention arm to this study being run by Dr. Ernest Schaefer of The Jean Mayer USDA Human Nutrition Center on Aging at Tufts University and Dr. Francine Welty of Beth Israel Deaconess Medical Center.
The lifestyle ruminate on, called Targeting INflammation using SALsalate to ban CardioVascular Disease (TINSAL-CVD), purpose look at the effects of lifestyle intervention (diet, distress and omega-3 fatty acid supplement) or salsalate compared to placebo to reduce rise or promote regression of unfalteringly and flexuous coronary artery calcification as assessed by multi-detector CT angiography, a to some degree new method to image the coronary arteries. Patients are randomized to lifestyle, salsalate or placebo with images of the coronary arteries at baseline and after 30 months of intervention.
A second study being headed by Drs. Goldfine and Shoelson is using salsalate in patients with type 2 diabetes to target redness and thus lower blood glucose. This sanctum sanctorum, called TINSAL-T2D, is ongoing and is funded by the National Organization of Diabetes and Digestive and Kidney Diseases. http://tinsalt2d.org
A third study headed by Dr. Goldfine and Dr. Peter Reaven of the Carl T. Hayden VA Medical Center in Phoenix targets inflammation using salsalate in patients with impaired glucose tolerance to make progress insulin sensitivity. This exploration, called TINSAL-IGT, is ongoing and is funded by the VA.
The various studies using salsalate in connection with treatment and prevention of diabetes stem from work initiated at Joslin dating back to the 1990s when the molecular target of high dose aspirin was identified. Dr. Shoelson, who holds the Helen and Morton Adler Chair and is Precede of the Section on Cellular and Molecular Physiology at Joslin, was the key to demonstrate the importance of this mutinous pathway, IKK/NFkB, in animal models of diet-induced weight and diabetes. These “bench” studies showed the benefits of aspirin in improving metabolism in these animals.
These ongoing studies, including the one-liner being reported today, show the advancement that has been made in alluring these lab studies and bringing them to patients in a to some degree short age of dead for now. After Shoelson’s initial discovery, some had considered looking to develop a new drug to aim IKK/NFkB, since it was known that aspirin had too great a risk of bleeding. But Goldfine came up with the idea of worrying salsalate, a dull already developed and on the market.
“This was substantial to hurriedness the bench to bedside observations as much of the pharmacokinetic and long-stipulations safety data is established,” she said. “Although the stimulant was around, no one ever thought of using it in diabetes/metabolic syndrome.”
Drugs currently available to treat diabetes do not completely butt the IKK/NFkB pathway. As a come to pass, these studies promise to lead to some novel therapies allowing for regarding the disease.
Alongside Joslin Diabetes Center
Joslin Diabetes Center is the world’s largest diabetes clinic, diabetes delving center and provider of diabetes education. Founded in 1898, Joslin is an sovereign nonprofit institution affiliated with Harvard Medical School. Joslin research is a cooperate of more than 300 people at the forefront of discovery aimed at preventing and curing diabetes. Joslin Clinic, attached with Beth Israel Deaconess Medical Center in Boston, the nationwide network of Joslin Affiliated Programs, and the hundreds of Joslin educational programs offered each year for clinicians, researchers and patients, empower Joslin to realize the potential of, implement and dividend innovations that immeasurably on life the lives of people with diabetes. As a nonprofit, Joslin benefits from the generosity of donors in advancing its mission.
Joslin Diabetes Center
One Joslin Pl.
Boston, MA 02215
United States
http://www.joslin.org